BioTech Medics has announced that they have entered into a wholesaler Distribution Agreement for BioTech’s patented and exclusive Shban Antimicrobial Hand Sanitizer Products with a Dubai distributor. The
ImThera Medical, has received Ethics Committee clearance to begin human clinical trials in Belgium. The trials will include ImThera’s Targeted Hypoglossal Neurostimulation (THN) Sleep Therapy to treat obstructive
Mankind has presented Afresa study data at the 45th Annual Meeting of the European Association for the Study of Diabetes. The data shows that Afresa Inhalation Powder is
PolyMedix has initiated dosing and commenced a second clinical trial, a phase 1B pilot proof of concept study, in the US with its anticoagulant reversing agent PMX-60056 under
The Special Committee of Independent Directors of Patheon and Lonza have announced the extension until October 15, 2009 of the exclusivity and due diligence period. The step is
Johnson & Johnson, through its subsidiary Ortho-McNeil-Janssen Pharmaceuticals, and Crucell have entered into a strategic collaboration focusing on the discovery, development and commercialisation of monoclonal antibodies and vaccines
UCB and AstraZeneca have entered into a partnership to register and commercialise UCB’s PEGylated anti-TNF alpha drug Cimzia (certolizumab pegol) in Brazil. The drug is to be registered
Abbott has announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay’s pharmaceuticals business for E4.5 billion ($6.6 billion) in cash. The transaction will provide
Onyx Pharmaceuticals has begun enrolling patients in a phase 1 study of ONX 0801, a novel alpha-folate receptor-mediated thymidylate synthase (TS) inhibitor, as a potential treatment for advanced
Merck & Co has entered into an exclusive agreement with CSL Biotherapies, a subsidiary of CSL Limited, to market and distribute CSL’s seasonal influenza vaccine Afluria in the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.